RNF43 p.G659fs 通过 PI3K/AKT/mTOR 信号通路和 HLA-E 上调导致 MSI-high 结直肠癌中 NK 细胞功能障碍
RNF43 p.G659fs leads to natural killer cell dysfunction in MSI-high colorectal cancer through PI3K/AKT/mTOR signaling and HLA-E up-regulation.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
将癌症免疫治疗转向新兴免疫检查点 TIGIT：这是否会突破传统方法的局限性？
英文原题：Turning Cancer Immunotherapy to the Emerging Immune Checkpoint TIGIT: Will This Break Through the Limitations of the Legacy Approach?
查看英文原题
Turning Cancer Immunotherapy to the Emerging Immune Checkpoint TIGIT: Will This Break Through the Limitations of the Legacy Approach?
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
免疫检查点（ICs）的发现将癌症治疗推向了下一个时代。作为一个新兴的免疫检查点，TIGIT/CD155轴通过多种途径抑制T细胞和NK细胞的细胞毒性。靶向TIGIT的免疫检查点抑制剂（ICIs）有望通过联合治疗解决抗PD-(L)1单克隆抗体（mAbs）无响应的问题。本文对TIGIT的表达、结构和作用机制，以及靶向TIGIT的mAbs的设计原则和方法及其临床数据提出了见解。本文还讨论了使用mAbs、双特异性和三特异性抗体（bsAbs和tsAbs）、多肽和化合物靶向TIGIT的优势和劣势，以及抗TIGIT与抗PD-1或癌症疫苗的潜在联合治疗。最后，讨论了当前靶向TIGIT的免疫疗法的前景。
展开英文摘要原文
The discovery of immune checkpoints (ICs) has pushed cancer treatment into the next era. As an emerging immune checkpoint, the TIGIT/CD155 axis inhibits the cytotoxicity of T and NK cells through multiple pathways. Immune checkpoint inhibitors (ICIs) targeting TIGIT are hopefully expected to address the issue of unresponsiveness to anti-PD-(L)1 monoclonal antibodies (mAbs) by combination therapy.
This paper presents insights on the expression, structure and mechanism of action of TIGIT, as well as the principles and methods of designing mAbs targeting TIGIT and their clinical data. The advantages and disadvantages of targeting TIGIT using mAbs, bispecific and tri-specific antibodies (bsAbs and tsAbs), peptides, and compounds, in addition to potential combination therapies of anti-TIGIT with anti-PD-1 or cancer vaccines, are addressed.
Finally, perspectives on current immunotherapies targeting TIGIT are discussed.
论文信息
- 作者
- Cui H、Elkord E
- 单位
- Department of Biosciences and Bioinformatics, School of Science, Suzhou Municipal Key Lab in Biomedical Sciences and Translational Immunology, Xi'an Jiaotong-Liverpool University, Suzhou 215123, China.China
- 期刊
- Vaccines2024 Nov 22
- 原文标识
- PubMed 39771968 · DOI 10.3390/vaccines12121306
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →